Biocon sees larger licensing income from pharma
Biocon , India’s top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said.
The Bangalore-based drugmaker earlier said consolidated net profit fell 15.8 percent in December quarter, while revenue rose 3 percent. The sales growth in the fiscal third quarter ended December 31 was flat on lower licensing income.The company said, licensing fees and income dropped to 292 million rupees in October-December from 768 million rupees a year earlier.
Biocons presence straddles four main therapeutic areas Diabetology, Cardiology, Nephrology and Oncology even as it plans to introduce two new divisions, Comprehensive Care, and Immunotherapy, this year.
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
